Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047]

T M Kim¹, M Taszner², S Novelli³, S-G Cho⁴, J C Villasboas⁵, M Merli⁶, A Jiménez-Ubieto⁷, B Tessoulin⁸, L M Poon⁹, D Tucker¹⁰, J Walewski¹¹, S Yi¹², Y Song¹³, G Chong¹⁴, E Bachy¹⁵, S Guidez¹⁶, A Alonso¹⁷, D Jagadeesh¹⁸, W Zhang¹⁹, L Magnano²⁰, E Iskierka-Jażdżwska²¹, M Tani²², B Shen²³, A Uppala²³, M Zhu²³, S Shariff²⁴, J Brouwer-Visser²³, A Chaudhry²³, H Mohamed²³, S Ambati²³, S Luminari²⁵; ELM-2 Investigators

Affiliations

¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: gabriel9@snu.ac.kr.
² Department of Haematology and Transplantology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
³ Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
⁴ Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
⁵ Mayo Clinic, Rochester, USA.
⁶ Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁷ Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
⁸ Hematology Department, Nantes University Hospital, Nantes, France.
⁹ Hematology Oncology National University Hospital, Singapore, Singapore.
¹⁰ Department of Hematology, Royal Cornwall Hospital, Truro, UK.
¹¹ Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warsaw, Poland.
¹² State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
¹³ Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China.
¹⁴ Department of Medical Oncology, and Clinical Haematology, Olivia Newton-John Cancer Centre, Heidelberg, Australia.
¹⁵ Department of Hematology, Lyon Sud Hospital, Lyon, France; Lymphoma Immuno-Biology (LIB) team, Inserm U1111, CIRI, Lyon, France.
¹⁶ Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, France.
¹⁷ Hospital Universitario Quiron Salud Madrid, Madrid, Spain.
¹⁸ Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, USA.
¹⁹ Hematology Department, Peking Union Medical College Hospital, Beijing, China.
²⁰ Hematology Department, Hospital Clínic of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
²¹ Copernicus Memorial Hospital, Department of General Hematology, Medical University of Łódź, Łódź, Poland.
²² Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy.
²³ Regeneron Pharmaceuticals, Inc., Tarrytown, USA.
²⁴ Regeneron UK Ltd., Uxbridge, UK.
²⁵ Division of Hematology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy.

PMID: 39627085
DOI: 10.1016/j.annonc.2024.11.009

Free article

Published Erratum

Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047]

T M Kim et al. Ann Oncol. 2025 Mar.

Free article

. 2025 Mar;36(3):352.

doi: 10.1016/j.annonc.2024.11.009. Epub 2024 Dec 2.

Authors

Affiliations

¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: gabriel9@snu.ac.kr.
² Department of Haematology and Transplantology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
³ Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
⁴ Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
⁵ Mayo Clinic, Rochester, USA.
⁶ Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁷ Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
⁸ Hematology Department, Nantes University Hospital, Nantes, France.
⁹ Hematology Oncology National University Hospital, Singapore, Singapore.
¹⁰ Department of Hematology, Royal Cornwall Hospital, Truro, UK.
¹¹ Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warsaw, Poland.
¹² State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
¹³ Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China.
¹⁴ Department of Medical Oncology, and Clinical Haematology, Olivia Newton-John Cancer Centre, Heidelberg, Australia.
¹⁵ Department of Hematology, Lyon Sud Hospital, Lyon, France; Lymphoma Immuno-Biology (LIB) team, Inserm U1111, CIRI, Lyon, France.
¹⁶ Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, France.
¹⁷ Hospital Universitario Quiron Salud Madrid, Madrid, Spain.
¹⁸ Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, USA.
¹⁹ Hematology Department, Peking Union Medical College Hospital, Beijing, China.
²⁰ Hematology Department, Hospital Clínic of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
²¹ Copernicus Memorial Hospital, Department of General Hematology, Medical University of Łódź, Łódź, Poland.
²² Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy.
²³ Regeneron Pharmaceuticals, Inc., Tarrytown, USA.
²⁴ Regeneron UK Ltd., Uxbridge, UK.
²⁵ Division of Hematology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy.

PMID: 39627085
DOI: 10.1016/j.annonc.2024.11.009

No abstract available

PubMed Disclaimer

Erratum for

Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżewska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Ann Oncol. 2024 Nov;35(11):1039-1047. doi: 10.1016/j.annonc.2024.08.2239. Epub 2024 Aug 13. Ann Oncol. 2024. PMID: 39147364 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047]

Affiliations

Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047]

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources